154
Views
4
CrossRef citations to date
0
Altmetric
Oncology

Predicting the radiosensitivity of HPV-negative oropharyngeal squamous cell carcinoma using miR-130b

, ORCID Icon, , , , , , ORCID Icon & show all
Pages 640-645 | Received 10 Dec 2020, Accepted 24 Feb 2021, Published online: 01 Apr 2021

References

  • Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.
  • Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014;32(27):2940–2950.
  • Mirghani H, Amen F, Tao Y, et al. Increased radiosensitivity of HPV-positive head and neck cancers: molecular basis and therapeutic perspectives. Cancer Treat Rev. 2015;41(10):844–852.
  • Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.
  • Moergel M, Abt E, Stockinger M, et al. Overexpression of p63 is associated with radiation resistance and prognosis in oral squamous cell carcinoma. Oral Oncol. 2010;46(9):667–671.
  • Su X, Chakravarti D, Cho MS, et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature. 2010;467(7318):986–990.
  • Rang Z, Wang ZY, Pang QY, et al. MiR-181a Targets PHLPP2 to Augment AKT Signaling and Regulate Proliferation and Apoptosis in Human Keloid Fibroblasts. Cell Physiol Biochem. 2016;40(3-4):796–806.
  • Shen L, Gan M, Li Q, et al. MicroRNA-200b regulates preadipocyte proliferation and differentiation by targeting KLF4. Biomed Pharmacother. 2018;103:1538–1544.
  • Zhang BL, Dong FL, Guo TW, et al. MiRNAs Mediate GDNF-Induced Proliferation and Migration of Glioma Cells. Cell Physiol Biochem. 2017;44(5):1923–1938.
  • Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer Gene Ther. 2010;17(8):523–531.
  • Zheng T, Wang J, Chen X, et al. Role of microRNA in anticancer drug resistance. Int J Cancer. 2010;126(1):2–10.
  • Allen KE, Weiss GJ. Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther. 2010;9(12):3126–3136.
  • Sarkar FH, Li Y, Wang Z, et al. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat. 2010;13(3):57–66.
  • Li BL, Lu C, Lu W, et al. miR-130b is an EMT-related microRNA that targets DICER1 for aggression in endometrial cancer. Med Oncol. 2013;30(1):484.
  • Colangelo T, Fucci A, Votino C, et al. MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer. Neoplasia. 2013;15(9):1086–1099.
  • Lai KW, Koh KX, Loh M, Singapore Gastric Cancer Consortium, et al. MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer. Eur J Cancer. 2010;46(8):1456–1463.
  • Marchini S, Marabese M, Marrazzo E, et al. DeltaNp63 expression is associated with poor survival in ovarian cancer. Ann Oncol. 2008;19(3):501–507.
  • Chen YK, Hsue SS, Lin LM. Immunohistochemical demonstration of p63 in DMBA-induced hamster buccal pouch squamous cell carcinogenesis. Oral Dis. 2003;9(5):235–240.
  • Liefer KM, Koster MI, Wang XJ, et al. Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res. 2000;60(15):4016–4020.
  • Westfall MD, Pietenpol JA. p63: Molecular complexity in development and cancer. Carcinogenesis. 2004;25(6):857–864.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.